Form 4: Sage Therapeutics Director Geno Germano Granted 21,500 Stock Options

Sage Therapeutics, Inc. director Geno J Germano was granted 21,500 stock options as part of the company's 2024 Equity Incentive Plan and Non-Employee Director Compensation Program.

Summary

• Geno J Germano, a Director of Sage Therapeutics, Inc. (SAGE), was granted 21,500 stock options.
• The transaction date for this acquisition was June 11, 2025.
• The stock options have an exercise price of $6.77 per share.
• These options were issued under the Sage Therapeutics, Inc. 2024 Equity Incentive Plan and in accordance with Sage's Non-Employee Director Compensation Program.
• The options will vest in full upon the earlier of June 11, 2026, or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, contingent on continued service as a director.
• The expiration date for these stock options is June 11, 2035.
• Following this transaction, Mr. Germano directly beneficially owns 21,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a standard, expected equity grant to a director, which is generally viewed as a positive for corporate governance and alignment of interests, but does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The award is part of a pre-established Non-Employee Director Compensation Program, indicating a structured approach to governance and compensation.

Future Outlook

The stock options granted to Director Geno J Germano are set to vest in full upon the earlier of June 11, 2026, or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, subject to his continued service as a director.

Management Comments

• Brandon Marsh, as Attorney-in-Fact for Geno J Germano, signed the Form 4.
• Geno Germano authorized Chris Benecchi (Chief Operating Officer), Greg Shiferman (Senior Vice President, General Counsel, and Secretary), Brandon Marsh (Senior Director, Corporate Counsel, and Assistant Secretary), and Stuart Falber of WilmerHale to prepare and sign SEC filings on his behalf.

Industry Context

This filing represents a routine equity compensation event for a non-employee director, a common practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to attract and retain experienced board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard component of compensation packages in public companies, including those in the biotech industry, aimed at incentivizing long-term performance and aligning director interests with shareholders.
• The specific terms, such as the number of options and vesting schedule, are typically determined by the company's compensation committee based on industry benchmarks for director compensation, though no specific comparable companies or projects are detailed in this document.

Corporate Governance

Related Party Transactions

• The grant of 21,500 stock options to Geno J Germano, a director of Sage Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board. This is a standard, pre-approved compensation mechanism for non-employee directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: No direct impact mentioned, but a well-governed company with aligned leadership can indirectly benefit all employees.

Next Steps

• Continued service of Geno J Germano as a director until the vesting conditions are met.
• Vesting of the 21,500 stock options upon the earlier of June 11, 2026, or the day prior to the 2026 Annual Meeting of Stockholders.

Key Dates

Keywords

Sage Therapeutics, SAGE, Stock Options, Equity Incentive Plan, Director Compensation, Beneficial Ownership, SEC Form 4, Insider Transaction